New Products and Industry News

Login toDownload PDF version

Patients With Diabetes Underuse Special Footwear

  A new study has found that patients with diabetes walk without wearing specialized footwear designed to prevent foot sores too often.

  According to research published in Diabetes Care, a new study of 107 diabetic patients found that 29% of steps by patients during a 2-week period were taken without the use of their custom-made shoes. Researchers also found that patients wore their preventive shoes less often at home than when they were outside of their house (39% compared to 87%, respectively).

  Visit http://care.diabetesjournals.org/content/early/2013/01/11/dc12-1330.abst... for more information.

FDA Import Alert Prompts Increase in US Production

  The United States Food and Drug Administration (FDA) recently announced an import alert on certain steam sterilized plastic bandages and cotton pads that are imported from China.

  In response, Covidien (Mansfield, MA) has increased manufacturing of its cotton-based wound care products made in the US to insure there are no disruptions in the supply of these materials. These products have been detained without physical examination due to microbiological contamination. Covidien does not import or distribute any of the steam-sterilized products affected by the FDA’s decision.

  Visit www.accessdata.fda.gov/cms_ia/importalert_227.html for more information.

Cardium Announces Distribution Agreement With Academy Medical

  Cardium Therapeutics (San Diego, CA) announced a distribution agreement with Academy Medical, LLC (Gainesville, Fl) to market, sell, and distribute Excellagen to United States government medical providers, including the Veterans Administration (VA) health care system and military hospitals. Excellagen is FDA-cleared, to support advanced wound care in a broad range of dermal wounds.

  Academy Medical’s initial focus will be to provide education and training on the use of Excellagen in the treatment of traumatic wounds; nonhealing venous, pressure and diabetic ulcers; limb salvage; and post-Mohs skin cancer surgery and to support distribution within its growing customer base of more than 35 VA and military hospitals within the US.

  For more information, visit www.cardiumthx.com

US Wound Care Management Market Outlook to 2018

  GlobalData’s (New York, NY) new report, “United States Wound Care Management Market Outlook to 2018 Advanced Wound Management, Wound Closure Devices, Pressure Relief Devices, Ostomy Drainage Bags and Others” provides key market data on the US Wound Care Management market. The report provides value, volume, and average price data for each segment and sub-segment within market categories: negative pressure wound therapy, wound closure devices, pressure relief devices, traditional wound management, compression therapy, advanced wound management, ostomy drainage bags, tissue engineering, wound debridement devices, and automated suturing devices. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

  This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

  For more information, visit www.globaldata.com.

Regenerative Tissue Matrix Receives Medicare Reimbursement

  Kinetic Concepts, Inc (KCI) announced that Medicare and Medicare Advantage Health plan beneficiaries living in 10 Midwestern states now have access to the KCI Graftjacket® regenerative tissue matrix (RTM) for the treatment of diabetic foot ulcers (DFUs).

  Graftjacket RTM was recently approved for coverage and reimbursement by Noridian Administrative Services, a Medicare Administrative Contractor MAC. This new Local Coverage Determination policy gives more than 3.7 million Medicare beneficiaries in 10 states of current Noridian jurisdiction — Arizona, Alaska, Idaho, Montana, North Dakota, South Dakota, Oregon, Utah, Washington, and Wyoming.

  This product is indicated for the repair or replacement of damaged or inadequate integumental tissue. Proprietary processing allows the body to accept Graftjacket RTM, and helps reduce the potential for a rejection response. The product is readily repopulated with the patient’s own cells and revascularized by the body. Ultimately, it acts as a scaffold that allows the body to convert the matrix to functional host tissue in wound repair.

  For more information, visit www.kci1.com.

Heavy-Duty Mid-Wheel Drive Wheelchair Launched

  Permobil, Inc (Lebanon, TN) launched the M300 Corpus® HD power wheelchair, further expanding its mid-wheel drive product lineup.

  Designed specifically for wheelchair users weighing up to 450 pounds, the new wheelchair is built to withstand the rigors of any heavy-duty lifestyle. Exclusively for the HD model, the M300 base has been both extended and widened, and the suspension has been strengthened for an overall more stable platform. Notable features of the chair include sturdy arm and leg rests, extra wide footplates for additional room, unmatched power tilt range of 0-45°, unprecedented power recline of 90-150°, and ultra-strong actuators for elevating feet above the heart

  For more information, visit www.permobil.com.

Wound Healing and Inflammation Patent Issued to BioChemics

  BioChemics (Danvers, MA) announced that the United States Patent and Trademark Office issued U.S. Patent No. 8,343,486, “Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation,” to BioChemics, Inc.

  The patent covers the use of various topical formulations for treating wounds, ulcers, and inflammatory conditions, including topical formulations comprising a combination of the retinoid Vitamin A and the blood vessel dilator methyl nicotinate in a stable emulsion. Also covered are topical formulations comprising a combination of a retinoid and the blood vessel dilators methyl nicotinate and arginine. The topical formulations may include additional or alternative retinoids or blood vessel dilators and also may include an antioxidant and/or a mitochondrial function promoter. The target medical conditions include a variety of wounds and ulcers associated with causes such as diabetic neuropathy, myopathy, cancer, or a physical injury to the location.

  For more information, visit www.biochemics.com.

Viridis BioPharma Launches Advanced Wound Care Dressings in India

  Quick-Med Technologies, Inc (Gainesville, FL) announced that Viridis BioPharma Pvt. Ltd (India) has begun selling and shipping Microfoam™ dressings to customers. Microfoam is an advanced wound care dressing utilizing Quick-Med’s proprietary nonleaching NIMBUS® technology. Viridis received approval by the United States Food and Drug Administration of India in September 2011 to manufacture and market the dressing.

  For more information, visit www.quickmedtech.com.

Nanodermatology Society Declares 2013 the Year of Topical Delivery

  The Nanodermatology Society (NDS) declared 2013 as the “Year of Topical Delivery.” Nano/microneedles and patches are already being standardized for vaccine delivery and have been developed for the flu vaccine. Gene therapy, which traditionally has required injections or infusions, now through nanodelivery systems, can deliver DNA and functional RNA to activate and suppress genes through the skin. The various targets for gene therapy include genetic diseases, inflammatory diseases, allergies, tumors, and wound healing. Infections caused by multidrug resistant bacteria such as methicillin resistant Staphylococcus aureus and Acinetobacter baumanni have been on the rise in the past decade and pose a serious threat to patients and the health care system. Nanodermatology is enhancing both the delivery and efficacy of known established antimicrobial agents, as well as allowing for the delivery of more volatile substances, such as nitric oxide, to active areas of infection.

  The NDS is a nonprofit organization founded in 2010 charged with monitoring nanotechnology as it relates to the diagnosis, prevention, and treatment of skin disease and evaluating their potential benefits or pitfalls.

  For more information, visit www.nanodermsociety.org.

Back to top